In a recent talk with Mike Milken from the Milken Institute, Kiran Mazumdar-Shaw shared her views on Compassionate Capitalism while talking about “Responding to Covid-19”.
“I’m very committed to compassionate capitalism, which is what I like to call my business….My products are there to help patients who need it anywhere in the world. And therefore, I believe that if I can actually produce these products in a way that provides affordable access…I will be very driven by that sense of purpose.”
In the podcast, she talks about her journey as an entrepreneur as well as about her latest drug Itolizumab which got compelling results in a proof-of-concept study in
India.
“We actually have a very exciting monoclonal antibody which we had developed for autoimmune indications like psoriasis and rheumatoid arthritis, which we are now repurposing for COVID-19 because of its very unique mechanism of action.”
She talks about problems in India and how the situation in India is a constant reminder that there are people who are really deprived. It teaches many things about life, because this realization is constantly evoking your conscience.
“The most fascinating part of India is that slums seem to have developed herd immunity because the sero surveillance that they did in some of the most congested slums in Mumbai and other parts of the country had in excess of 50% to 60% positive antibodies, which means that these very congested areas have actually developed herd immunity, which is a good thing.”
COVID has brought a lot of spotlight on how India should look at the future. The podcast talks about what Kiran Mazumdar-Shaw thinks that India is now focusing on.
Listen to the full podcast here:
Transcript of the Audio: Conversations with MM – Kiran Mazumdar Shaw, Biocon – August 18, 2020
Link to Milken Institute Website: https://milkeninstitute.org/podcast/biocon-kiran-mazumdar-developing-COVID-treatment
